Can gene editing with CRISPR technology help fight cardiovascular disease? Can looking beyond the known FH genes help personalize risk assessment? Join Dr. Kiran Musunuru, Penn Medicine, and Dr. Amit V. Khera, Broad Institute, as we discuss and debate.
- Latest data on CRISPR-Cas 9 for PCSK9 and ANGPTL3 mutations
- Impact of polygenic “background” on monogenic risk in FH
- Suggested framework for cascade screening of individuals with FH and severe hypercholesterolemia